Immunization Newsbriefs
Link to Main Page
  Back Search the Site Send Your Feedbck  
Immunization Newsbriefs
Read Current Issue Online
Search Newsbriefs Archives
Subscribe to Email Online
Unsubscribe from Email Online
About NNii
Vaccine Information
Health Professionals
Policy Makers
Read Current Newsbriefs

Nabi Restarts Staph Vaccine Testing
Fort Lauderdale Sun-Sentinel; 3D
Singer, Glenn


Nabi Biopharmaceuticals' experimental StaphVAX vaccine is entering its second clinical trial after the first round of tests showed the vaccine, which aims to reduce the risk of Staphylococcus aureus infection, was effective for about 10 months in patients with end-stage renal disease. The company had hoped the vaccine would protect patients for 12 months, and the Food and Drug Administration (FDA) requested that a new trial with an attainable goal be conducted before a decision on approval is made. The new trial will involve 3,300 patients on hemodialysis at 200 sites in the United States. StaphVAX could receive FDA approval as early as 2006.

© Copyright National Network for Immunization Information. The information contained in the National Network for Immunization Information Web site should not be used as a substitute for the medical care and advice of your health care provider. There may be variations in treatment that your health care provider may recommend based on individual facts and circumstances.